NEW YORK – Genomadix said Friday that it has entered into a license agreement with Mayo Clinic under which the two will collaborate on the delivery of enhanced telestroke services in the US.
Under the terms of the agreement, Mayo Clinic will grant Genomadix access to its technical expertise in the telestroke space, collaborating with the company to expand the use of its US Food and Drug Administration-cleared pharmacogenomic testing platform, the Genomadix Cube CYP2C19 System, into sites that incorporate remote technologies to care for patients experiencing a stroke.
Genomadix's Cube platform uses real-time quantitative PCR to generate CYP2C19 genotype results in about one hour, allowing clinicians to make rapid decisions on how and when to use certain antiplatelet therapies.
The company's CYP2C19 test was recently adopted by Stanford Medical Center, and the firm is now exploring new applications for the Cube system in other disease areas.